000282543 001__ 282543
000282543 005__ 20251201102734.0
000282543 0247_ $$2doi$$a10.1093/nop/npaf101
000282543 0247_ $$2ISSN$$a2054-2577
000282543 0247_ $$2ISSN$$a2054-2585
000282543 037__ $$aDZNE-2025-01306
000282543 041__ $$aEnglish
000282543 082__ $$a610
000282543 1001_ $$00009-0006-2919-8622$$aZeyen, Thomas$$b0
000282543 245__ $$aProof of concept: Portable ultra-low-field MRI for the assessment of brain tumors
000282543 260__ $$aOxford$$bOxford Univ. Press$$c2025
000282543 3367_ $$2DRIVER$$aarticle
000282543 3367_ $$2DataCite$$aOutput Types/Journal article
000282543 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764581171_18439
000282543 3367_ $$2BibTeX$$aARTICLE
000282543 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282543 3367_ $$00$$2EndNote$$aJournal Article
000282543 520__ $$aBackgroundHigh-field (HF) MRI is a standard diagnostic tool for brain cancer, but its high cost and technical demands limit accessibility in low- and middle-income countries. Recent advancements in ultra-low field (ULF) MRI technology, including the development of portable scanners, offer a promising solution to these challenges. This study evaluates the diagnostic capabilities of ULF-MRI in detecting brain cancer and compares radiological evaluation using ULF- with HF-MRI.MethodsConsecutive patients with suspected or confirmed brain tumors undergoing routine 3T HF-MRI at the University Hospital Bonn were recruited for this study and underwent ULF-MRI. Eligible patients were at least 18 years old and had MRI-abnormalities in the HF-MRI. The 0.064 Tesla Swoop portable MR Imaging System was utilized. HF-MRI and ULF-MRI scans were independently evaluated by two experienced neuroradiologists and results were compared.ResultsThirteen patients were recruited, of whom 11 (85%) were diagnosed with brain tumors. In 11/11 (100%) patients with brain tumors, ULF-MRI identified tumor lesions corresponding to the findings of HF-MRI. In 7/11 (63.6%) identification of all tumor lesions could be achieved. Three of four further relevant imaging findings in HF-MRI (e.g. acute hydrocephalus or concomitant ischemia) were also found in in ULF-MRI.ConclusionThis single-center study demonstrates that ULF-MRI is a practical tool in neuro-oncology, which may particularly be helpful in resource-limited settings. Further research is required to define the role of ULF-MRI alongside existing imaging modalities for brain cancer diagnosis and management.
000282543 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282543 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000282543 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000282543 7001_ $$0P:(DE-2719)9000732$$aSabir, Hemmen$$b1$$udzne
000282543 7001_ $$0P:(DE-2719)9002598$$aBauer, Tobias$$b2
000282543 7001_ $$aHenke, Oliver$$b3
000282543 7001_ $$aLehnen, Nils$$b4
000282543 7001_ $$aZidan, Mousa$$b5
000282543 7001_ $$aOlbrich, Simon$$b6
000282543 7001_ $$aLange, Annalena$$b7
000282543 7001_ $$aBisten, Justus$$b8
000282543 7001_ $$aGroteklaes, Anne$$b9
000282543 7001_ $$0P:(DE-2719)2811327$$aFaber, Jennifer$$b10$$udzne
000282543 7001_ $$aRöver, Lea$$b11
000282543 7001_ $$aSchäfer, Niklas$$b12
000282543 7001_ $$00000-0001-5818-5392$$aWeller, Johannes$$b13
000282543 7001_ $$aBruchhausen, Walter$$b14
000282543 7001_ $$0P:(DE-2719)9001861$$aRadbruch, Alexander$$b15$$udzne
000282543 7001_ $$aHerrlinger, Ulrich$$b16
000282543 7001_ $$00000-0002-6180-7671$$aRüber, Theodor$$b17
000282543 773__ $$0PERI:(DE-600)2768945-1$$a10.1093/nop/npaf101$$gp. npaf101$$pnpaf101$$tNeuro-oncology practice$$vAOP$$x2054-2577$$y2025
000282543 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282543 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002598$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000282543 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811327$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000282543 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001861$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000282543 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282543 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000282543 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL PRACT : 2022$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000282543 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000282543 9201_ $$0I:(DE-2719)5000032$$kAG Sabir$$lNeonatal Neuroscience$$x0
000282543 9201_ $$0I:(DE-2719)5000075$$kAG Radbruch$$lClinical Neuroimaging$$x1
000282543 9201_ $$0I:(DE-2719)1011401$$kClinical Research Platform (CRP)$$lClinical Research Platform (CRP)$$x2
000282543 980__ $$ajournal
000282543 980__ $$aVDB
000282543 980__ $$aI:(DE-2719)5000032
000282543 980__ $$aI:(DE-2719)5000075
000282543 980__ $$aI:(DE-2719)1011401
000282543 980__ $$aUNRESTRICTED